Format

Send to

Choose Destination
Antiviral Res. 2011 Jan;89(1):71-4. doi: 10.1016/j.antiviral.2010.11.008. Epub 2010 Nov 18.

Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.

Author information

1
Department of Biological Sciences, Florida Gulf Coast University, Fort Myers, FL 33965, USA. cnicholson@fgcu.edu

Abstract

Severe dengue virus (DENV) disease symptoms, including dengue hemorrhagic fever and dengue shock syndrome, have been correlated with the presence of pre-existing antibodies that enhance rather than neutralize infections in Fc receptor bearing cells. These antibodies can originate from previous infection with a different serotype of dengue, or from waning antibody titers that occur in infants and young children as they are weaned from breast milk that contains protective dengue-specific antibodies. Despite the apparent importance of this antibody dependent enhancement (ADE) effect, there has been no description of any specific inhibitors of this process. We explored DENV entry inhibitors as a potential strategy to block ADE. Two different peptide entry inhibitors were tested for the ability to block antibody-mediated DENV-2 infection of human, FcRII bearing K562 cells in vitro. Both peptides were able to inhibit ADE, showing that entry inhibitors are possible candidates for the development of specific treatment for severe DENV infection.

PMID:
21093488
DOI:
10.1016/j.antiviral.2010.11.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center